Article
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Hepatology (Baltimore, Md.) - 1 Jul 2015
Alqahtani Saleh A, Afdhal Nezam, Zeuzem Stefan, Gordon Stuart C, Mangia Alessandra, Kwo Paul, Fried Michael, Yang Jenny C, Ding Xiao, Pang Phillip S, McHutchison John G, Pound David, Reddy K Rajender, Marcellin Patrick, Kowdley Kris V, Sulkowski Mark
Abstract excerpt
UNLABELLED: In phase III studies, treatment with the once-daily fixed-dose combination tablet of ledipasvir/sofosbuvir (LDV/SOF) with and without ribavirin (RBV) resulted in high rates of sustained virological response (SVR) in patients chronically infected with genotype 1 hepatitis C virus, including those with compensated cirrhosis. We conducted an analysis of data from these trials to compare the safety and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.